Top Markets
#1 GoPlus Security GoPlus Security +31.51%
#2 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.70%
#3 Status Status +17.55%
#4 Wrapped NXM Wrapped NXM +14.47%
#5 BankrCoin BankrCoin +11.13%
#6 Pons Pons +10.73%
#7 Bedrock Bedrock +10.01%
#8 Ontology Gas Ontology Gas +9.25%
#9 DMT-NAT DMT-NAT +8.78%
#10 o1.exchange o1.exchange +7.41%
Coin of the day
GoPlus Security GoPlus Security
Innstillinger
Språk
NORSK
Valuta
USD
Tema
Vectus Biosystems Limited Vectus Biosystems Limited

Vectus Biosystems Limited

VBS
Rangering i aksjer #33746
Vectus Biosystems Limited, an Australian medical research and development firm,... Vectus Biosystems Limited, an Australian medical research and development firm, specializes in devising therapies for fibrotic conditions and hypertension. Its pharmaceutical pipeline addresses ailments affecting the heart, kidneys, liver, and lungs. The company's leading experimental drug, VB0004, aims to counter the degradation of functional tissue resulting from fibrosis, scarring, and elevated blood pressure. Furthermore, Vectus intends to advance treatments for hepatic fibrotic diseases, such as non-alcoholic steatohepatitis, and various pulmonary fibrotic disorders. Beyond its therapeutic endeavors, the company also provides AccuCal and RealCount software, tools engineered to enhance the swiftness and precision of DNA and RNA quantification in laboratory settings. Established in 2005, Vectus Biosystems is headquartered in Rosebery, Australia.
Aksjekurs
$0.11284557
Markedsverdi
$6.98M
Endring (1 dag)
0.00%
Endring (1 år)
162.85%
Land
AU
Handel Vectus Biosystems Limited (VBS)

Kategori

Healthcare
Inntekter for Vectus Biosystems Limited (VBS)
Inntekter i Aug 2026 TTM: 0
Ifølge de nyeste økonomiske rapportene til Vectus Biosystems Limited er selskapets nåværende inntekter (TTM) 0. I 2026 hadde selskapet inntekter på 0 lik inntektene i 2026, som var 0. Inntektene er det totale beløpet et selskap genererer fra salg av varer eller tjenester. I motsetning til fortjeneste trekkes ingen kostnader fra.
Inntektshistorikk for Vectus Biosystems Limited fra 2026 til 2026
Inntekter ved slutten av hvert år
År Inntekter Endre
Ikke nok data for de angitte datoene.
Inntekter for lignende selskaper eller konkurrenter
Selskap Inntekter Forskjell i inntekter Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE